Every Form 4 that MaxCyte, Inc. (MXCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MXCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MXCT filings page.
Johnston John Joseph reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director John Joseph Johnston received 30,421 restricted stock units, each representing one share of common stock, as part of his annual non-employee director grant. He also received a stock option for 49,579 shares at $1.13 per share, expiring in 2036. The RSUs vest on June 17, 2027, subject to continued service, bringing his direct common stock holdings to 201,581 shares.
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director Rekha Hemrajani reported equity awards consisting of restricted stock units and stock options. She received 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with a strike price of $1.13 per share, expiring on June 16, 2036. The annual grant for non-employee directors vests on June 17, 2027, subject to her continuous service, bringing her direct common stock holdings to 70,314 shares.
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one common share, and an option for 49,579 shares at an exercise price of $1.13 per share, expiring on June 16, 2036. The RSUs vest on June 17, 2027, subject to his continued service, and his direct common stock holdings after the grant total 428,749 shares.
MAXCYTE, INC. director Douglas Richard reported awards of restricted stock units and stock options as part of his compensation. He acquired 30,421 RSUs, each representing one future share of common stock, and 49,579 stock options to buy common shares at $1.13 per share.
The annual grants were made under the company’s equity grant policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, assuming he continues to serve. After the RSU grant, his direct common stock holdings total 260,998 shares.
MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.
MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options. He was granted 30,421 shares of Common Stock in the form of restricted stock units, each representing a right to one share. These RSUs vest on June 17, 2027, if he continues serving as a non-employee director under the company’s Equity Grant Policy. He was also granted stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share, expiring on June 16, 2036. Following these awards, he directly holds 181,300 shares of Common Stock.
MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with an exercise price of $1.13 per share. The RSU grant was made under the company’s equity grant policy for non-employee directors and is scheduled to vest on June 17, 2027, contingent on his continued service. Following the RSU grant, Balthrop directly holds 80,998 shares of common stock. The stock options, which are also directly held, are exercisable into 49,579 shares of common stock and are scheduled to expire on June 16, 2036.
MAXCYTE, INC. director Yasir B. Al-Wakeel received equity awards as part of his annual non-employee director compensation. He was granted 30,421 shares of Common Stock in the form of restricted stock units, plus stock options for 49,579 shares at an exercise price of $1.13 per share.
The RSUs and option grant were made under the company’s Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, contingent on his continued service. Following the RSU grant, he directly owns 80,998 shares of Common Stock.
Ahuja Parmeet reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja reported an equity award of 187,500 shares of Common Stock in the form of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock at no purchase price.
According to the filing, 25% of the RSUs will vest on March 30, 2027, and the remaining RSUs will vest in three equal annual installments after that date, subject to Ahuja’s continued service with the company through each vesting date. Following this grant, Ahuja directly holds 187,500 shares reported in this Form 4.
MAXCYTE, INC. Chief Financial Officer Parmeet Ahuja received a grant of employee stock options covering 375,000 shares of Common Stock. The options have an exercise price of $0.6762 per share and expire on March 29, 2036.
According to the vesting schedule, 25% of the shares underlying this option vest on March 30, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, Ahuja holds 375,000 stock options directly.
MAXCYTE, INC. President and CEO Masoud Maher received an equity compensation package consisting of stock options and restricted stock units. He was granted an option to buy 600,000 shares of common stock at an exercise price of $0.684 per share, expiring on March 26, 2036. Twenty-five percent of these option shares vest on March 27, 2027, with the rest vesting in 36 equal monthly installments, as long as he continues serving the company. He also received 300,000 restricted stock units, each representing one share of common stock. Twenty-five percent of the RSUs vest on March 27, 2027, and the remaining units vest in three equal annual installments, again contingent on continued service. Following the RSU grant, he holds 475,000 common shares directly. These are compensation-related awards, not open-market purchases or sales.
MAXCYTE, INC. Chief Financial Officer Douglas J. Swirsky reported an open-market sale of 10,142 shares of common stock at a weighted average price of $0.815 per share. The shares were sold automatically to cover tax withholding due upon the vesting of previously granted RSUs, and are described as a non-discretionary “sale to cover” transaction. After this sale, Swirsky directly holds 151,669 shares of MaxCyte common stock.